Approved indications: In the United States, oral pyrimethamine (Daraprim) is approved only for the treatment of toxoplasmosis when used together with a sulfonamide antibiotic, in adults and children, including congenital and ocular or cerebral toxoplasmosis.

Off-label uses (evidence-based):

• Prevention of toxoplasmosis in high-risk patients (such as those with advanced HIV or after organ transplantation), usually combined with a sulfonamide or clindamycin plus folinic acid (leucovorin).
• Alternative prophylaxis regimens for Pneumocystis jirovecii pneumonia (PCP) when trimethoprim–sulfamethoxazole cannot be used (e.g., with dapsone and leucovorin).
• Historical use for malaria treatment and prophylaxis against susceptible Plasmodium species; because resistance is common and safer, better-studied antimalarials exist, this role is now largely limited and typically not used for routine travel prophylaxis.

Efficacy expectations: In toxoplasmosis, fever and other systemic symptoms often improve over several days, while neurologic or eye findings may take 1–2 weeks or longer to clearly improve and radiologic lesions can take weeks to months to resolve; when combined appropriately with a sulfonamide and leucovorin, pyrimethamine-based regimens have high cure and relapse-prevention rates but require prolonged therapy and careful monitoring. Compared with alternatives such as high-dose trimethoprim–sulfamethoxazole, pyrimethamine regimens remain a standard for severe CNS or ocular toxoplasmosis, though alternatives are often favored when cost, access, or bone-marrow toxicity are concerns.

Typical dosing and how to take it: For treatment of toxoplasmosis, adults usually start with 50–75 mg of pyrimethamine by mouth once daily together with a sulfonamide antibiotic for 1–3 weeks, then continue at about half that daily dose for an additional 4–5 weeks or longer as clinically needed; children generally receive 1 mg/kg/day (divided into two doses) for a few days, then 0.5 mg/kg/day for about a month, along with weight-adjusted sulfonamide dosing. Folinic acid (leucovorin) is typically given throughout therapy to protect the bone marrow. Tablets are taken orally once daily (or in divided doses), with or without food, though taking them with food can reduce stomach upset; a pharmacy can prepare a liquid suspension for patients who cannot swallow tablets.

Special dosing instructions: Doses often need adjustment based on age, weight, kidney and liver function, co-administered myelosuppressive drugs, and blood-count results, with lower starting doses in older adults or those with significant comorbidities. In patients allergic or intolerant to sulfonamides, pyrimethamine may be combined with other agents (such as clindamycin or atovaquone) according to specialist guidance, but folinic acid rescue and blood-count monitoring remain essential.

Missed dose guidance: If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next dose; in that case, skip the missed dose and resume the regular schedule, without doubling doses to “catch up.”

Overdose: Taking more than prescribed can rapidly cause severe gastrointestinal symptoms, seizures, and dangerous bone-marrow suppression; suspected overdose warrants immediate emergency care or contact with a poison control center, and treatment may include gastric decontamination, seizure control, intensive supportive care, and prompt administration of folinic acid.

Common side effects: The most frequent problems are decreased appetite, nausea, and vomiting (often improved by taking doses with food), along with possible mild rash, fatigue, or headache; blood count changes such as mild neutropenia can occur, especially at higher doses or with concomitant sulfonamides.

Serious or rare adverse effects: Pyrimethamine can cause severe skin reactions (including Stevens–Johnson syndrome and toxic epidermal necrolysis), anaphylaxis, marked bone-marrow suppression (megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia), tongue inflammation, blood in the urine, heart rhythm disturbances, and, with overdose, seizures and life-threatening toxicity; any rash, unexplained fever, sore throat, paleness, easy bruising, dark urine, chest pain, or irregular heartbeat requires urgent medical attention.

Warnings and precautions: The drug has a narrow therapeutic window, and folinic acid (leucovorin) is routinely given to reduce bone-marrow toxicity, with periodic blood counts (more often when using high doses). Use requires caution in people with kidney or liver disease, pre-existing folate deficiency, malabsorption, alcoholism, seizure disorders, or G6PD deficiency (especially when combined with sulfonamides). In pregnancy, animal data show teratogenicity, so use is generally avoided and reserved for situations where expected benefit clearly outweighs fetal risk, with specialist oversight and leucovorin; the drug enters breast milk, so breastfeeding decisions must balance infant risk and maternal need. Children are particularly vulnerable to overdose, and accidental ingestion has been fatal.

Relative safety compared with other options: Compared with some alternative regimens (such as trimethoprim–sulfamethoxazole), pyrimethamine-based therapy carries a higher risk of serious bone-marrow toxicity and severe skin reactions and therefore requires closer laboratory monitoring and folinic acid rescue, but it remains an important option when maximal anti–Toxoplasma efficacy is needed.

Side-effect reporting and safety updates: Patients and caregivers should promptly inform their clinician about any suspected side effects; adverse events can be reported directly to the FDA MedWatch program (online or by phone) to contribute to ongoing safety monitoring and updated recommendations.

Major drug interactions: Concomitant use with other antifolate or bone-marrow–suppressing drugs—such as sulfonamides (including high-dose sulfadiazine), trimethoprim–sulfamethoxazole, proguanil, methotrexate, certain chemotherapy agents, or zidovudine—increases the risk of severe anemia, leukopenia, or thrombocytopenia and requires close blood-count monitoring or alternative regimens. Phenytoin and other antiepileptics that affect folate metabolism may also heighten marrow toxicity, and rare hepatotoxicity has been reported with lorazepam plus pyrimethamine.

Other medicines, supplements, foods, and alcohol: Patients should review all prescription and nonprescription drugs, herbal products, and vitamins with their clinician before starting pyrimethamine, as high-dose folate supplements may alter its effects and should be managed carefully in relation to prescribed folinic acid (leucovorin). No specific food or beverage interactions are known, but taking doses with food can lessen nausea, and limiting alcohol is advisable to reduce added liver strain.

Conditions requiring extra caution: Use is cautious or sometimes avoided in people with significant kidney or liver impairment, pre-existing megaloblastic anemia or other blood dyscrasias, known folate deficiency, malabsorption, alcoholism, seizure disorders, or G6PD deficiency (particularly when a sulfonamide is co-prescribed). Pregnancy and breastfeeding require individualized risk–benefit assessment and specialist input.

Monitoring needs: During treatment—especially at higher doses—patients usually need regular complete blood counts with platelets (often at least weekly, and semiweekly for high-dose regimens), and, in longer courses, periodic kidney and liver function tests; clinicians may also monitor for cardiac arrhythmias in patients with underlying heart disease or symptoms such as palpitations. There are no specific interactions with imaging contrast agents, but patients should inform radiology staff that they are taking pyrimethamine.

Q: What is pyrimethamine used for?
A: In the U.S., pyrimethamine by mouth is primarily used, together with a sulfonamide antibiotic and folinic acid (leucovorin), to treat toxoplasmosis affecting the brain, eyes, or other organs, and it may also be used off-label to prevent toxoplasmosis or Pneumocystis pneumonia in certain high-risk patients.

Q: How long will I need to take pyrimethamine?
A: Treatment for toxoplasmosis is usually prolonged—often at least 6 weeks for acute therapy and sometimes months of lower-dose maintenance in people with weakened immune systems—so your total duration will depend on how severe the infection is, how well you tolerate the medicine, and how your scans and blood tests respond.

Q: Why do I have to take folinic acid (leucovorin) with this medicine?
A: Pyrimethamine can strongly suppress the bone marrow, leading to serious anemia and low white blood cell or platelet counts, and folinic acid helps protect normal cells from this effect without significantly reducing the drug’s activity against the parasite.

Q: Can I take pyrimethamine if I am pregnant or breastfeeding?
A: Because animal studies show a risk of birth defects and the drug enters breast milk, pyrimethamine is generally avoided in pregnancy and during breastfeeding unless specialists judge that the benefits clearly outweigh the risks and can monitor you and the baby closely.

Q: What should I do if I feel very sick or develop a rash while taking pyrimethamine?
A: Stop taking the medicine and seek urgent medical care if you develop a new rash, peeling skin, fever, sore throat, paleness, easy bruising, dark urine, chest pain, or an irregular heartbeat, as these may signal serious reactions that need immediate evaluation.

Q: Are there medicines or supplements I should avoid with pyrimethamine?
A: You should not start or stop any antibiotics, chemotherapy, seizure medicines, or folate-containing supplements without checking first, because several of these can greatly increase the risk of bone-marrow problems or change how well pyrimethamine works.

Storage: Store tablets at room temperature (59–77°F / 15–25°C), in a dry place, protected from light, in the original tightly closed container, and always keep them out of the reach of children.

Disposal: For unused or expired pyrimethamine, use a pharmacy or community drug take-back program when available; if none is available, place tablets (preferably in their container) mixed with an undesirable substance (such as used coffee grounds or cat litter) in a sealed bag before discarding in household trash, and do not flush the medication unless specifically instructed by product directions or local authorities.